Dr. Edward C. Ray, M.D.
Plastic Surgery (Plastic and Reconstructive Surgery Physician)
8700 Beverly Blvd
West Hollywood, CA 90048
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Mayo Medical School (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 78
Licensed in California since 2016, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: Mayo Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Plastic and Reconstructive Surgery Physician primary
CA license A91870 (first issued 2016; current) · NC license 2008-01037
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cedars-Sinai Medical Center Los Angeles, CA
Medical groups
- Cedars-Sinai Medical Care Foundation (1,692 clinicians)
- Cedars-Sinai Medical Center (799 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 78
- Services billed
- 202
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| New patient office or other outpatient visit, 45-59 minutes | 21 | 21 |
| New patient office or other outpatient visit, 30-44 minutes | 19 | 19 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 13 |
| Implantation of biologic implant to soft tissue | 13 | 13 |
| Reconstruction of breast using tissue expander | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 9 companies reported 20 payments worth $19,994 in total to this clinician.
| Pfizer Inc. | $11,100 |
|---|---|
| Ethicon Inc. | $7,332 |
| Rti Surgical, Inc | $615 |
| Tela Bio, Inc. | $342 |
| Integra Lifesciences Corporation | $320 |
| Davol Inc. | $155 |
| Biocircuit Technologies Inc | $62.97 |
| Becton, Dickinson and Company | $39.58 |
| Compensation for services other than consulting (speaking, faculty) | $11,100 |
|---|---|
| Consulting Fee | $6,350 |
| Food and Beverage | $1,821 |
| Travel and Lodging | $722 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ethicon Inc. Sep 4, 2025 | Consulting Fee | $6,350 |
| Pfizer Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) XTANDI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Pfizer Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) XTANDI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Pfizer Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) XTANDI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Ethicon Inc. Jul 31, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $654 |
| Ethicon Inc. Aug 11, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $68.11 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $30,905 in research payments for these studies, mostly to the institutions running them.
- Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
AbbVie Inc. · Recruiting · NCT06575192
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.